FindTrial
Sign In

HCT

BEHAVIORAL4 trials

Sponsors

Centers for Disease Control and Prevention, Actinium Pharmaceuticals

Conditions

AMLAcute Myelogenous LeukemiaAcute Myeloid LeukemiaBone Marrow TransplantHIV InfectionsLeukemia, Acute MyelogenousLeukemia, Acute MyeloidLeukemia, Myeloid, Acute

Phase 2

No Excuses/Sin Buscar Excusas Intervention to Reduce Latino Men's HIV Risks
CompletedNCT00690690
Centers for Disease Control and PreventionHIV Infections
Start: 2008-06-30End: 2009-11-30Updated: 2010-03-09

Phase 3

Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
Active, not recruitingNCT02665065
Actinium PharmaceuticalsAcute Myelogenous Leukemia, Acute Myeloid Leukemia, AML +6
Start: 2016-06-30End: 2026-12-31Updated: 2023-07-19

Unknown Phase

Proyecto SOL: A Risk Reduction Intervention for Hispanic Men Who Have Sex With Men (MSM)
CompletedNCT00690976
Centers for Disease Control and PreventionHIV Infections
Start: 2008-07-31End: 2010-03-31Target: 220Updated: 2010-03-11
Project ICARE: Intervening for Community Awareness, Respect, & Empowerment
CompletedNCT00712088
Centers for Disease Control and PreventionHIV Infections
Start: 2008-07-31End: 2010-03-31Target: 275Updated: 2010-03-11

Related Papers

Randomized Phase III SIERRA Trial of <sup>131</sup> I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML
Journal of Clinical Oncology2024-09-1911 citations
131I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML
Blood2023-11-022 citations
High-Dose Targeted Radiation with 131I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML
Blood2023-11-022 citations
131I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors
Blood2023-11-021 citations
S248: SIERRA TRIAL RESULTS WITH A TARGETED RADIOTHERAPY, IOMAB-B, A MYELOABLATIVE CONDITIONING WITH REDUCED INTENSITY TOLERABILITY YIELDS HIGH CR, LONG TERM SURVIVAL IN HSCT INELIGIBLE ACTIVE R/R AML
HemaSphere2023-08-017 citations
Where do we stand with radioimmunotherapy for acute myeloid leukemia?
2022-03-3112 citations
Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies
Blood2021-11-059 citations
Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered
Blood2020-11-049 citations
High Doses of Targeted Radiation with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia
Blood2020-11-047 citations
Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Allogeneic Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial
Biology of Blood and Marrow Transplantation2020-01-232 citations
Antibodies to watch in 2020.
2020-01-01328 citations
Re-Induction and Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial
Blood2019-11-134 citations
Rapid reduction of peripheral blasts in older patients with refractory acute myeloid leukemia (AML) using reinduction with single agent anti-CD45 targeted iodine (<sup>131</sup>I) apamistamab [Iomab-B] radioimmunotherapy in the phase III SIERRA trial.
Journal of Clinical Oncology2019-05-207 citations
Targeted Conditioning of Iomab-B (131I-anti-CD45) Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Relapsed or Refractory Acute Myeloid Leukemia (AML): Preliminary Feasibility and Safety Results from the Prospective, Randomized Phase 3 Sierra Trial
Blood2018-11-2911 citations